BridgeBio CEO Neil Kumar at BIO22 (J.T. MacMillan Photography for Endpoints News)

With PhII suc­cess, Bridge­Bio wades deep­er in­to dwarfism drug de­bate

Bridge­Bio’s ex­per­i­men­tal drug de­signed to treat com­pli­ca­tions of achon­dropla­sia, or dwarfism, great­ly sur­passed Wall Street ex­pec­ta­tions Mon­day morn­ing in the fi­nal co­hort of a Phase II tri­al, send­ing the com­pa­ny’s stock climb­ing high.

In­fi­gra­tinib, an oral small mol­e­cule drug tar­get­ing the gene that caus­es dwarfism, in­duced rough­ly three-cen­time­ters-per-year faster growth com­pared to base­line in 10 pa­tients af­ter six months, Bridge­Bio said Mon­day. The com­pa­ny has al­ready start­ed en­rolling pa­tients for a Phase III tri­al and will take this co­hort’s dose — 0.25 mg/kg — in­to the piv­otal study, CEO Neil Ku­mar told End­points News.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.